Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

Pier Luigi Zinzani, Armando Santoro, Arturo Chiti, Secondo Lastoria, Antonio Pinto, Lugi Rigacci, Giovanni Barosi, Martina Pennisi, Paolo Corradini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients’ response and treatment length, management of PD-1 blockade therapy–treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

Original languageEnglish
JournalLeukemia and Lymphoma
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Hodgkin Disease
Blocking Antibodies
Stem Cell Transplantation
Therapeutics
Uncertainty
Recurrence

Keywords

  • checkpoint inhibitors
  • Hodgkin lymphoma
  • practice guidelines

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

@article{a8d21105f78f43c1a91e062327261f69,
title = "Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma",
abstract = "Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients’ response and treatment length, management of PD-1 blockade therapy–treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.",
keywords = "checkpoint inhibitors, Hodgkin lymphoma, practice guidelines",
author = "Zinzani, {Pier Luigi} and Armando Santoro and Arturo Chiti and Secondo Lastoria and Antonio Pinto and Lugi Rigacci and Giovanni Barosi and Martina Pennisi and Paolo Corradini",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1519808",
language = "English",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",

}

TY - JOUR

T1 - Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma

AU - Zinzani, Pier Luigi

AU - Santoro, Armando

AU - Chiti, Arturo

AU - Lastoria, Secondo

AU - Pinto, Antonio

AU - Rigacci, Lugi

AU - Barosi, Giovanni

AU - Pennisi, Martina

AU - Corradini, Paolo

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients’ response and treatment length, management of PD-1 blockade therapy–treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

AB - Programmed death 1 (PD-1) blocking antibodies now represent a major advance in the treatment of patients with classical Hodgkin lymphoma (cHL) who relapse after autologous stem cell transplantation (ASCT) and pre- and/or post-ASCT brentuximab vedotin or after at least three lines of therapy. However, uncertainties still remain on the optimal use of these agents in refractory Hodgkin disease. A panel of experts was convened to produce a consensus document aimed at providing practice recommendations for the optimal use of PD-1 blocking antibodies in cHL, especially on pretreatment selection and evaluation of cHL patients’ response and treatment length, management of PD-1 blockade therapy–treated patients, evaluation and management of toxicity. Our hope is that these recommendations might help hematologists to improve optimal management of patients with pretreated cHL.

KW - checkpoint inhibitors

KW - Hodgkin lymphoma

KW - practice guidelines

UR - http://www.scopus.com/inward/record.url?scp=85055037475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055037475&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1519808

DO - 10.1080/10428194.2018.1519808

M3 - Article

AN - SCOPUS:85055037475

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -